---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-011072"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2024-08-23T23:59:59+00:00"
generated_at: "2026-05-31T07:51:27.380006+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# ENDRA Life Sciences appoints new CEO, raises $8M, reduces annual OpEx by $3.1M

## Summary
- New acting CEO Alexander Tokman appointed; CFO Richard Jacroux and Regulatory head Ziad Rouag join.
- Gross proceeds of $8.0M from public offering of common stock and warrants.
- Annualized operating expenses reduced by $3.1M (26%) vs prior year; Q2 OpEx $2.2M.
- Cash and cash equivalents $6.4M at June 30, 2024.
- Advanced FDA regulatory process; initiated new pilot trials at two North American sites.

## SEC filing metadata
- accession: 0001654954-24-011072
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2024-08-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495424011072/0001654954-24-011072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495424011072/endra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-011072
- JSON: https://secwatch.observer/filing/0001654954-24-011072.json
- Plain text: https://secwatch.observer/filing/0001654954-24-011072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.